Clinical Trial Update: A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating TAR-210 versus single-agent intravesical therapy for non-muscle invasive bladder cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• TAR-210

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Status: RECRUITING